Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
936.00    0.00 (0.00%)
Bid:
932.00
Ask:
942.00
Spread: 10.00 (1.073%)
Market Cap: £256.19m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Acquisition

7 Feb 2006 07:02

Gooch & Housego PLC07 February 2006 For Immediate Release 7 February 2006 Gooch & Housego PLC ACQUISITION OF CHROMODYNAMICS, INC. Gooch & Housego, the specialist manufacturer of advanced optoelectroniccomponents, materials, instruments and systems, is pleased to announce that ithas acquired ChromoDynamics, Inc. (CDI). Based in the USA, CDI is a developer ofhyperspectral imaging systems. Designed initially for use in conjunction withhigh-end research microscopes, the products are targeted at biomedical research,drug development and medical diagnostics. Future products will address a broadrange of applications including remote sensing and semiconductor inspectionsystems. CDI was founded in 1997 to transfer technology developed at Carnegie MellonUniversity ("CMU"), Pittsburgh, Pennsylvania, into the commercial realm, andbenefited from grants from the National Institutes of Health (NIH) and otherfunding bodies. CDI licenses key patents from CMU (exclusive to its targetmarkets) and has also developed its own intellectual property. Biomedicalimaging systems based on this technology have the potential to improve detectionof cancer and aid in drug development. Three first generation products have beensold to leading biomedical research and pharmaceutical organisations, and afourth to a manufacturer of semiconductor inspection equipment. CDI is now ready to commercialise the technology and make the transition fromresearch and development to production. Manufacturing resources and expertisewithin Gooch & Housego in acousto-optic tuneable filters (the key activecomponent in the system), spectroscopic instrumentation and electronics willenable CDI to achieve the scale necessary to address the market opportunity.Initial sales are expected in the 2007 financial year. The current sole employeeand co-founder will remain with CDI as Vice President of R&D and will providethe foundation for the new team. The consideration for the acquisition is $1,180,000 payable in cash oncompletion. During the year to 30 June 2005, CDI had an income of $229k and made a loss of$78,000. As at 31 May 2005, CDI had net assets of $26,000. Contacts: Gareth Jones, Chairman and Chief Executive Officer, 01460 52271 Tim Thompson, Buchanan Communication Ltd, 020 7466 5000 Andrew Edwards, Oriel Securities Limited, 020 7710 7600 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Dec 20137:00 amRNSPreliminary Results
26th Nov 20137:00 amRNSAcquisition of Constelex Technology Enablers Ltd
1st Nov 20137:00 amRNSNotification of Preliminary Results
29th Oct 201312:06 pmRNSHolding(s) in Company
15th Oct 201310:17 amRNSHolding(s) in Company
15th Oct 20137:00 amRNSAcquisition of Spanoptic Limited
8th Oct 201311:21 amRNSHolding(s) in Company
7th Oct 20137:00 amRNSFull-Year Trading Update
1st Oct 201311:52 amRNSHolding(s) in Company
18th Sep 20137:00 amRNSCapital Markets Day
9th Sep 20132:38 pmRNSHolding(s) in Company
25th Jul 20135:54 pmRNSHolding(s) in Company
25th Jul 20135:52 pmRNSHolding(s) in Company
12th Jul 20133:12 pmRNSDirector/PDMR Shareholding
12th Jul 20133:11 pmRNSDirector/PDMR Shareholding
12th Jul 20133:09 pmRNSDirector/PDMR Shareholding
12th Jul 20133:07 pmRNSDirector/PDMR Shareholding
12th Jul 20133:05 pmRNSDirector/PDMR Shareholding
11th Jun 20137:00 amRNSSales and Marketing drive
11th Jun 20137:00 amRNSInterim Report
9th May 20137:00 amRNSNotification of Interim Results
10th Apr 20137:00 amRNSNew Long Term Incentive Plan and grant of Awards
8th Apr 20137:00 amRNSHalf Year Trading Update
19th Mar 201310:44 amRNSAnnual Report and Accounts
15th Mar 201310:50 amRNSHolding(s) in Company
1st Mar 20134:09 pmRNSDirector/PDMR Shareholding
1st Mar 20134:05 pmRNSDirector/PDMR Shareholding
1st Mar 20134:03 pmRNSDirector/PDMR Shareholding
1st Mar 20134:01 pmRNSDirector/PDMR Shareholding
28th Feb 20137:00 amRNSResults of Annual General Meeting
27th Feb 201311:24 amRNSAIM Disclosure Update
27th Feb 20137:00 amRNSTrading Update
4th Feb 20133:00 pmRNSAdditional Listing
18th Jan 20132:12 pmRNSDirector/PDMR Shareholding
18th Jan 20132:11 pmRNSDirector/PDMR Shareholding
18th Jan 20132:09 pmRNSDirector/PDMR Shareholding
10th Jan 20133:00 pmRNSAdditional Listing
7th Jan 20137:00 amRNSValue Creation Plan Crystallises
13th Dec 20124:43 pmRNSHolding(s) in Company
27th Nov 20127:00 amRNSPreliminary Results
23rd Oct 20129:34 amRNSHolding(s) in Company
15th Oct 201211:02 amRNSHolding(s) in Company
5th Oct 20127:00 amRNSDirector change
4th Oct 20127:00 amRNSFull-Year Trading Update
25th Sep 20129:53 amRNSHolding(s) in Company
24th Sep 20122:09 pmRNSAdditional Listing
19th Sep 20128:47 amRNSAdditional Listing
19th Sep 20128:45 amRNSDirector/PDMR Shareholding
4th Sep 20122:14 pmRNSHolding(s) in Company
4th Sep 201210:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.